Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Humacyte, Inc.HUMA · Entity 6478 | Director · Chief Surgical Officer | August 26, 2021 | August 27, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Humacyte, Inc.
Report date August 26, 2021 · Filed August 27, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,877 |
Reported balance
After 2021-08-26 transaction · row 1
1 source rowRow 1 · 2021-08-26 · Grant · Acquired 7,877 · Balance 7,877 F1: On August 26, 2021, Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each share of Legacy Humacyte stock was exchanged for 0.2626 shares of common stock of Humacyte, Inc. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.56 · Expires 2025-12-11 | Direct | 90,595 |
Reported balance
After 2021-08-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-08-26 · Grant · Acquired 90,595 · Balance 90,595 F3: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2: Options are fully vested and exercisable. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.44 · Expires 2026-12-15 | Direct | 65,649 |
Reported balance
After 2021-08-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-08-26 · Grant · Acquired 65,649 · Balance 65,649 F3: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2: Options are fully vested and exercisable. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.54 · Expires 2028-04-12 | Direct | 118,168 |
Reported balance
After 2021-08-26 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-08-26 · Grant · Acquired 118,168 · Balance 118,168 F3: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2: Options are fully vested and exercisable. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.48 · Expires 2028-06-28 | Direct | 1,194,815 |
Reported balance
After 2021-08-26 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-08-26 · Grant · Acquired 1,194,815 · Balance 1,194,815 F3: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2: Options are fully vested and exercisable. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.28 · Expires 2030-12-14 | Direct | 1,575 |
Reported balance
After 2021-08-26 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-08-26 · Grant · Acquired 1,575 · Balance 1,575 F3: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F4: Options to purchase 2,625 shares of Common Stock granted on 12/14/2020, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Accordingly, columns 5, 7, and 9 of Table II report the number of securities equal to three-fifths of the 12/14/2020 option grant. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 26, 2021, Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each share of Legacy Humacyte stock was exchanged for 0.2626 shares of common stock of Humacyte, Inc.
F2: Options are fully vested and exercisable.
F3: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc.
F4: Options to purchase 2,625 shares of Common Stock granted on 12/14/2020, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Accordingly, columns 5, 7, and 9 of Table II report the number of securities equal to three-fifths of the 12/14/2020 option grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 26, 2021 Filed Aug 27, 2021 16:10 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 1,575 | Not disclosed Strike: $10.28 | Not disclosed |
DisclosureSEC source: 0001104659-21-110526 · tm2125954-17_4seq1.xml · derivative · entry 6 Lawson Jeffrey Harold · CIK 0001879530 · Director · Chief Surgical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,575 Underlying: Common Stock · 1,575 shares Expires 2030-12-14 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F4 · derivative.exercise_date: Options to purchase 2,625 shares of Common Stock granted on 12/14/2020, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Accordingly, columns 5, 7, and 9 of Table II report the number of securities equal to three-fifths of the 12/14/2020 option grant. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:10 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 1,194,815 | Not disclosed Strike: $8.48 | Not disclosed |
DisclosureSEC source: 0001104659-21-110526 · tm2125954-17_4seq1.xml · derivative · entry 5 Lawson Jeffrey Harold · CIK 0001879530 · Director · Chief Surgical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,194,815 Underlying: Common Stock · 1,194,815 shares Expires 2028-06-28 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:10 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 118,168 | Not disclosed Strike: $6.54 | Not disclosed |
DisclosureSEC source: 0001104659-21-110526 · tm2125954-17_4seq1.xml · derivative · entry 4 Lawson Jeffrey Harold · CIK 0001879530 · Director · Chief Surgical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,168 Underlying: Common Stock · 118,168 shares Expires 2028-04-12 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:10 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 65,649 | Not disclosed Strike: $3.44 | Not disclosed |
DisclosureSEC source: 0001104659-21-110526 · tm2125954-17_4seq1.xml · derivative · entry 3 Lawson Jeffrey Harold · CIK 0001879530 · Director · Chief Surgical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,649 Underlying: Common Stock · 65,649 shares Expires 2026-12-15 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:10 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 90,595 | Not disclosed Strike: $2.56 | Not disclosed |
DisclosureSEC source: 0001104659-21-110526 · tm2125954-17_4seq1.xml · derivative · entry 2 Lawson Jeffrey Harold · CIK 0001879530 · Director · Chief Surgical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,595 Underlying: Common Stock · 90,595 shares Expires 2025-12-11 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:10 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantCommon Stock | 7,877 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-110526 · tm2125954-17_4seq1.xml · nonDerivative · entry 1 Lawson Jeffrey Harold · CIK 0001879530 · Director · Chief Surgical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,877 F1 · price: On August 26, 2021, Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each share of Legacy Humacyte stock was exchanged for 0.2626 shares of common stock of Humacyte, Inc. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.